Targeted infection of HIV-1 Env expressing cells by HIV(CD4/CXCR4) ventors reveals a potential new rationale for HIV-1 mediated down-modulation of CD4

Retrovirology

Volumn 2, Issue , 2005, Pages

  Ye, Zhiping ^a,b   Harmison, George G ^a   Ragheb, Jack A ^c   Schubert, Manfred ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^c NATIONAL EYE INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; NEOMYCIN; VIRUS ENVELOPE PROTEIN; VIRUS VECTOR;

ANIMAL CELL; ARTICLE; CELL ADHESION; CELL COUNT; CELL POPULATION; CELL SPECIFICITY; CELL SURFACE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VIVO STUDY; INFECTION PREVENTION; NONHUMAN; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; RECEPTOR BINDING; SIGNAL TRANSDUCTION; STRUCTURE ANALYSIS; SUPERINFECTION; TARGET CELL; VIRUS REPLICATION; ANIMAL; CELL STRAIN 3T3; CELL STRAIN COS1; CERCOPITHECUS; DOWN REGULATION; GENE VECTOR; GENETIC TRANSDUCTION; HELA CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; MOUSE; PATHOGENICITY; PHYSIOLOGY; VIRION; VIRUS ASSEMBLY;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

ANIMALS; ANTIGENS, CD4; CELL ADHESION; CERCOPITHECUS AETHIOPS; COS CELLS; DOWN-REGULATION; GENE PRODUCTS, ENV; GENETIC VECTORS; HELA CELLS; HIV-1; HUMANS; MICE; NIH 3T3 CELLS; RECEPTORS, CXCR4; TRANSDUCTION, GENETIC; VIRION; VIRUS ASSEMBLY;

EID: 29944431988     PISSN: 17424690     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/1742-4690-2-80     Document Type: Article

References (66)

1. Maddon PJ, Dalgleish AG, McDougal JS, Clapham PR, Weiss RA, Axel R: The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain. Cell 1986,47:333-348.
2. Weiss RA: Receptor molecule blocks HIV. Nature 1988, 331:15.
3. Chaudhary VK, Mizukami T, Fuerst TR, Fitzgerald DJ, Moss B, Pastan I, Berger EA: Selective killing of HIV infected cells by recombinant human CD4-Pseudomonas exotoxin hybrid protein. Nature 1988, 335:369-372.
4. Young JAT, Bates P, Willert K, Varmus HE: Efficient incorporation of human CD4 protein into avian leukosis virus particles. Science 1990, 250:1421-1423.
5. Schubert M, Joshi B, Blondel D, Harmison GG: Insertion of the human immunodeficiency virus CD4 receptor into the envelope of vesicular stomatitis virus. J Virol 1992, 66:1579-1589.
6. Paik SY, Banerjea A, Chen CJ, Ye Z, Harmison GG, Schubert M: Defective HIV-1 provirus encoding a multitarget-ribozyme inhibits accumulation of spliced and unspliced HIV-1 mRNAs, reduces infectivity of viral progeny, and protects the cells from pathogenesis. Hum Gene Ther 1997, 8:1115-1124.
7. Schubert M, Banerjea AC, Paik S-Y, Harmison GG, Chen C-J: Targeted defective interfering HIV-1 particles as renewable antivirals? In Technical advances in AIDS research in the human nervous system. Edited by Major EO, Levy JA. New York: Plenum Press; 1995: 327-351
8. Schnell MJ, Johnson JE, Buonocore L, Rose JK: Construction of a novel virus that targets HIV-1-infected cells and controls HIV-1 infection [see comments]. Cell 1997, 90:849-857.
9. Mebatsion T, Finke S, Weiland F, Conzelmann KK: A CXCR4/CD4 pseudotype rhabdovirus that selectively infects HIV-1 envelope protein-expressing cells [see comments]. Cell 1997, 90:841-847.
10. Matano T, Odawara T, Iwamoto A, Yoshikura H: Targeted infection of a retrovirus bearing a CD4-Env chimera into human cells expressing human immunodeficiency virus type 1. J Gen Virol 1995, 76 ( Pt 12):3165-3169.
11. Endres MJ, Jaffer S, Haggarty B, Turner JD, Doranz BJ, O'Brien PJ, Kolson DL, Hoxie JA: Targeting of HIV- and SIV-infected cells by CD4-chemokine receptor pseudotypes. Science 1997, 278:1462-1464.
12. Campbell SM, Crowe SM, Mak J: Lipid rafts and HIV-1: from viral entry to assembly of progeny virions. J Clin Virol 2001, 22:217-227.
13. Schnell MJ, Buonocore L, Kretzschmar E, Johnson E, Rose JK: Foreign glycoproteins expressed from recombinant vesicular stomatitis viruses are incorporated efficiently into virus particles. Proc Natl Acad Sci U S A 1996, 93:11359-11365.
14. Orentas RJ, Hildreth JE: Association of host cell surface adhesion receptors and other membrane proteins with HIV and SIV. AIDS Res Hum Retroviruses 1993, 9:1157-1165.
15. Mebatsion T, Conzelmann KK: Specific infection of CD4+ target cells by recombinant rabies virus pseudotypes carrying the HIV-1 envelope spike protein. Proc Natl Acad Sci U S A 1996, 93:11366-11370.
16. Little LM, Lanman G, Huang AS: Immunoprecipitating human antigens associated with vesicular stomatitis virus grown in HeLa cells. Virology 1983, 129:127-136.
17. Little LM, Zavada J, Der CJ, Huang AS: Identity of HeLa cell determinants acquired by vesicular stomatitis virus with a tumor antigen. Science 1983, 220:1069-1071.
18. Hioe CE, Bastiani L, Hildreth JE, Zolla-Pazner S: Role of cellular adhesion molecules in HIV type 1 infection and their impact on virus neutralization [In Process Citation). AIDS Res Hum Retroviruses 1998, 14 Suppl 3:S247-254.
19. Cantin R, Methot S, Tremblay MJ: Plunder and stowaways: incorporation of cellular proteins by enveloped viruses. J Virol 2005, 79:6577-6587.
20. Paquette JS, Fortin JF, Blanchard L, Tremblay MJ: Level of ICAM-1 surface expression on virus producer cells influences both the amount of virion-bound host ICAM-1 and human immunodeficiency virus type 1 infectivity. J Virol 1998, 72:9329-9336.
21. Tardif MR, Tremblay MJ: Presence of host ICAM-1 in human immunodeficiency virus type 1 virions increases productive infection of CD4+ T lymphocytes by favoring cytosolic delivery of viral material. J Virol 2003, 77:12299-12309.
22. Tardif MR, Tremblay MJ: LFA-1 is a key determinant for preferential infection of memory CD4+ T cells by human immunodeficiency virus type 1. J Virol 2005, 79:13714-13724.
23. Lama J: The physiological relevance of CD4 receptor down-modulation during HIV infection. Current HIV Research 2003, 1:167-184.
24. Levesque K, Finzi A, Binette J, Cohen EA: Role of CD4 receptor down-regulation during HIV-1 infection. Current HIV Research 2004, 2:51-59.
25. Willey RL, Maldarelli F, Martin MA, Strebel K: Human immunodeficiency virus type 1 vpu protein induces rapid degradation of CD4. J Virol 1992, 66:7193-7200.
26. Garcia JV, Miller AD: Serine phosphorylation-independent downregulation of cell surface CD4 by nef. Nature 1991, 350:508-511.
27. Jabbar MA, Nayak DP: Intracellular interaction of human immunodeficiency virus type 1 (ARV-2) envelope glycoprotein gp160 with CD4 blocks the movement and maturation of CD4 to the plasma membrane. J Virol 1990, 64:6297-6304.
28. Levesque K, Zhao YS, Cohen EA: Vpu exerts a positive effect on HIV-1 infectivity by down-modulating CD4 receptor molecules at the surface of HIV-1-producing cells. J Biol Chem 2003, 278:28346-28353.
29. Lama J, Mangasarian A, Trono D: Cell-surface expression of CD4 reduces RIV-1 infectivity by blocking Env incorporation in a Nef- and Vpu-inhibitable manner. Curr Biol 1999, 9:622-631.
30. Bour S, Perrin C, Strebel K: Cell surface CD4 inhibits HIV-1 particle release by interfering with Vpu activity. J Biol Chem 1999, 274:33800-33806.
31. Chen BK, Gandhi RT, Baltimore D: CD4 down-modulation during infection of human T cells with human immunodeficiency virus type 1 involves independent activities of vpu, env, and nef. J Virol 1996, 70:6044-6053.
32. Rhee SS, Marsh JW: Human immunodeficiency virus type 1 Nef-induced down-modulation of CD4 is due to rapid internalization and degradation of surface CD4. J Virol 1994, 68:5156-5163.
33. Cortes MJ, Wong-Staal F, Lama J: Cell surface CD4 interferes with the infectivity of HIV-1 particles released from T cells. J Biol Chem 2002, 277:1770-1779.
34. Lee SW, Kahn ML, Dichek DA: Expression of an anchored urokinase in the apical endothelial cell membrane. Preservation of enzymatic activity and enhancement of cell surface plasminogen activation. J Biol Chem 1992, 267:13020-13027.
35. Shimada T, Fujii H, Mitsuya H, Nienhuis AW: Targeted and highly efficient gene transfer into CD4+ cells by a recombinant human immunodeficiency virus retroviral vector. J Clin Invest 1991, 88:1043-1047.
36. Pear WS, Nolan GP, Scott ML, Baltimore D: Production of high-titer helper-free retroviruses by transient transfection. Proc Natl Acad Sci USA 1993, 90:8392-8396.
37. Bess JW. Jr., Gorelick RJ, Bosche WJ, Henderson LE, Arthur LO: Microvesicles are a source of contaminating cellular proteins found in purified HIV-1 preparations. Virology 1997, 230:134-144.
38. Bazan HA, Alkhatib G, Broder CC, Berger EA: Patterns of CCR5, CXCR4, and CCR3 usage by envelope glycoproteins from human immunodeficiency virus type 1 primary isolates. J Virol 1998, 72:4485-4491.
39. Feng Y, Broder CC, Kennedy PE, Berger EA: HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor [see comments]. Science 1996, 272:872-877.
40. Lallos LB, Laal S, Hoxie JA, Zolla-Pazner S, Bandres JC: Exclusion of HIV coreceptors CXCR4, CCR5, and CCR3 from the HIV envelope. AIDS Res Hum Retroviruses 1999, 15:895-897.
41. Dimitrov DS, Hillman K, Manischewitz J, Blumenthal R, Golding H: Kinetics of soluble CD4 binding to cells expressing human immunodeficiency virus type 1 envelope glycoprotein. J Virol 1992, 66:132-138.
42. Keller GA, Siegel MW, Caras IW: Endocytosis of glycophospholipid-anchored and transmembrane forms of CD4 by different endocytic pathways. Embo J 1992, 11:863-874.
43. Truneh A, Buck D, Cassatt DR, Juszczak R, Kassis S, Ryu SE, Healey D, Sweet R, Sattentau Q: A region in domain 1 of CD4 distinct from the primary gp120 binding site is involved in HIV infection and virus-mediated fusion. J Biol Chem. 1991, 266:5942-5948.
44. Kimpton J, Emerman M: Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene. J Virol 1992, 66:2232-2239.
45. Schnittman SM, Lane HC, Roth J, Burrows A, Folks TM, Kehrl JH, Koenig S, Berman P, Fauci AS: Characterization of GP120 binding to CD4 and an assay that measures ability of sera to inhibit this binding. J Immunol 1988, 141:4181-4186.
46. Lifson JD, Feinberg MB, Reyes GR, Rabin L, Banapour B, Chakrabarti S, Moss B, Wong-Staal F, Steimer KS, Engleman EG: Induction of CD4-dependent cell fusion by the HTLV-III/LAV envelope glycoprotein. Nature 1986, 323:725-728.
47. Sodroski J, Goh WC, Rosen C, Campbell K, Haseltine WA: Role of the HTLV-III/LAV envelope in syncytium formation and cytopathicity. Nature 1986, 322:470-474.
48. Leonard R, Zagury D, Desportes I, Bernard J, Zagury JF, Gallo RC: Cytopathic effect of human immunodeficiency virus in T4 cells is linked to the last stage of virus infection. Proc Natl Acad Sci U S A 1988, 85:3570-3574.
49. Embretson J, Zupancic M, Beneke J, Till M, Wolinsky S, Ribas JL, Burke A, Haase AT: Analysis of human immunodeficiency virus-infected tissues by amplification and in situ hybridization reveals latent and permissive infections at single-cell resolution. Proc Natl Acad Sci U S A 1993, 90:357-361.
50. Humeau LM, Binder GK, Lu X, Slepushkin V, Merling R, Echeagaray P, Pereira M, Slepushkina T, Barnett S, Dropulic LK, Carroll R, Levine BL, June CH, Dropulic B: Efficient lentiviral vector-mediated control of HIV-1 replication in CD4 lymphocytes from diverse HIV+ infected patients grouped according to CD4 count and viral load. Mol Ther 2004, 9:902-913.
51. Lu X, Yu Q, Binder GK, Chen Z, Slepushkina T, Rossi J, Dropulic B: Antisense-mediated inhibition of human immunodeficiency virus (HIV) replication by use of an HIV type 1-based vector results in severely attenuated mutants incapable of developing resistance. J Virol 2004, 78:7079-7088.
52. Esser MT, Graham DR, Coren LV, Trubey CM, Bess JW, Jr., Arthur LO, Ott DE, Lifson JD: Differential incorporation of CD45, CD80 (B7-1), CD86 (B7-2), and major histocompatibility complex class I and II molecules into human immunodeficiency virus type 1 virions and microvesicles: implications for viral pathogenesis and immune regulation. J Virol 2001, 75:6173-6182.
53. Trubey CM, Chertova E, Coren LV, Hilburn JM, Hixson CV, Nagashima K, Lifson JD, Ott DE: Quantitation of HLA class II protein incorporated into human immunodeficiency type 1 virions purified by anti-CD45 immunoaffinity depletion of microvesicles. J Virol 2003, 77:12699-12709.
54. Hrecka K, Swigut T, Schindler M, Kirchhoff F, Skowronski J: Nef proteins from diverse groups of primate lentiviruses downmodulate CXCR4 to inhibit migration to the chemokine stromal derived factor 1. J Virol 2005, 79:10650-10659.
55. Chen M-Y, Maldarelli F, Karczewski MK, Willey RL, Strebel K: Human immunodeficiency virus type 1 vpu protein induces degradation of CD4 in vitro: the cytoplasmic domain of CD4 contributes to vpu sensitivity. J Virol 1993, 67:3877-3884.
56. Vincent MJ, Raja NU, Jabbar M: Human immunodeficiency virus type 1 vpu protein induces degradation of chimeric envelope glycoproteins bearing the cytoplasmic and anchor domains of CD4: role of the cytoplasmic domain in vpu-induced degradation in the endoplasmic reticulum. J Virol 1993, 67:5538-5549.
57. Ewart GD, Sutherland T, Gage PW, Cox GB: The Vpu protein of human immunodeficiency virus type 1 forms cation-selective ion channels. J Virol 1996, 70:7108-7115.
58. Ewart GD, Mills K, Cox GB, Gage PW: Amiloride derivatives block ion channel activity and enhancement of virus-like particle budding caused by HIV-1 protein Vpu. Eur Biophys J 2002, 31:26-35.
59. Ewart GD, Nasr N, Naif H, Cox GB, Cunningham AL, Gage PW: Potential new anti-human immunodeficiency virus type 1 compounds depress virus replication in cultured human macrophages. Antimicrob Agents Chemother 2004, 48:2325-2330.
60. Weiss CD, White JM: Characterization of stable Chinese hamster ovary cells expressing wild- type, secreted, and glycosylphosphatidylinositol-anchored human immunodeficiency virus type 1 envelope glycoprotein. J Virol 1993, 67:7060-7066.
61. Jonak ZL, Clark RK, Matour D, Trulli S, Craig R, Henri E, Lee EV, Greig R, Debouck C: A human lymphoid recombinant cell line with functional human immunodeficiency virus type 1 envelope. AIDS Res Hum Retroviruses 1993, 9:23-32.
62. Adachi A, Glendelman BE, Koenig S, Folks T, Willey R, Rabsom A, Martin M: Production of acquired immunodeficiency syndrome associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol 1986, 59:284-291.
63. Reiser J, Harmison G, Kluepfel-Stahl S, Brady RO, Karlsson S, Schubert M: Transduction of nondividing cells using pseudotyped defective high- titer HIV type 1 particles. Proc Natl Acad Sci U S A 1996, 93:15266-15271.
64. Earl PL, Koenig S, Moss B: Biological and immunological properties of human immunodeficiency virus type 1 envelope glycoprotein: analysis of proteins with truncations and deletions expressed by recombinant vaccinia viruses. J Virol 1991, 65:31-41.
65. Earl PL, Hugin AW, Moss B: Removal of cryptic poxvirus transcription termination signals from the human immunodeficiency virus type 1 envelope gene enhances expression and immunogenicity of a recombinant vaccinia virus. J Virol 1990, 64:2448-2451.
66. Fuerst TR, Niles EG, Studier FW, Moss B: Eukaryotic transient-expression system based on recombinant vaceinia virus that synthesizes bacteriophage T7 RNA polymerase. Proc Natl Acad Sci USA 1986, 83:8122-8126.